查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715404

人體肝臟模型市場（按模型類型、細胞來源、應用和最終用戶）—2025-2030 年全球預測

Human Liver Model Market by Model Type, Cell Source, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計人體肝臟模型市場規模在 2024 年將達到 15.5 億美元，在 2025 年將達到 16.8 億美元，在 2030 年將達到 25.4 億美元，複合年成長率為 8.53%。

主要市場統計數據
基準年2024年 15.5億美元
預計2025年 16.8億美元
預測年份 2030 25.4億美元
複合年成長率（%） 8.53%

過去十年來，人類肝臟模型的開發和完善速度大大加快，並已達到生物醫學研究和藥物開發的關鍵階段。在精準醫療和創新治療策略處於前沿的時代，深入了解肝臟模型變得至關重要。本報告深入探討了肝臟模型的演變，研究了先進方法和新技術的整合，重新定義了肝臟生理學、疾病建模和毒性評估的方法。隨著研究問題的不斷升級和監管要求的不斷加強，對忠實重現人類肝功能的模型的需求比以往任何時候都更加迫切。研究人員、臨床醫生和決策者都面臨著複雜的選擇，從傳統的2D培養到動態的3D系統，每種系統都具有獨特的優勢並解決了傳統方法的特定限制。目前的情況特徵是向更複雜、生理相關的體外環境發生重大轉變，這不僅受到技術創新的推動，也受到臨床前試驗中對可操作資料日益成長的需求的推動。在此背景下，該報告對人類肝臟模型研究未來的變革性轉變、細分細微差別、區域趨勢和關鍵參與者進行了系統性的研究。

推動肝臟建模技術發展的變革性轉變

近年來，人類肝臟模型周圍的環境正在發生重大變化。實驗生物學、電腦模擬和生物工程的技術融合使得能夠創建以前所未有的精度模擬人體肝臟複雜結構和功能的模型。組織工程的重大進展使研究人員能夠建構比傳統2D培養更好地包含細胞基質相互作用的3D結構。此外，體外和混合模型的整合透過將天然組織的真實性與工程系統的可控性相結合，彌合了傳統的差距。In Silico模擬的出現進一步加速了資料分析和預測，允許即時調整和改進模型保真度。

這一轉變的亮點是檢驗和最佳化的迭代過程，它現在已成為模型開發的一個組成部分。這使得新模型不僅成為藥物發現和毒理學研究的有效平台，也成為生理學研究的有力工具。在技​​術方面，自動化和高通量篩檢對加速這些進步做出了巨大貢獻。隨著研究不斷完善其重現人類肝臟複雜行為的能力，向更俱生物學相關性的方法的模式轉移也刺激了學術界、工業界和監管機構之間加強合作。此次合作凸顯了該行業充滿活力和動力的本質，該行業將持續的技術創新與嚴謹的科學探索相結合。

影響市場動態的關鍵細分洞察

深入研究細分可以發現一些對於定義市場動態和未來成長軌跡至關重要的基本趨勢。根據模型類型分析市場，已經採用了各種不同的技術，包括 2D 模型、 3D模型、體外模型、混合構建體、電腦模型、肝臟類器官等等。每種模型在生物相關性和擴充性方面都具有獨特的優勢，使研究人員能夠針對藥物發現和毒理學研究中的特定問題。選擇範圍很廣，從永生化肝細胞株和原代人類肝細胞到幹細胞衍生模型，每種模型都有不同程度的生理準確性和可重複性。

此外，以應用為中心的細分凸顯了這些模型的雙重作用。雖然借助模擬代謝途徑和訊號傳遞，藥物發現仍然是一個主要的應用領域，但教育部門已從生理學和毒理學研究的進步中受益匪淺。這種雙重關注促進了對肝功能的全面了解，並強調了透過真實世界資料增強的新的教育實踐。此外，根據最終用戶的細分，市場進一步分為生技公司、受託研究機構、製藥公司和研究機構。最終用戶概況的多樣性不僅反映了這些模型在不同領域的廣泛應用，也表明對適合每個細分市場特定要求的客製化肝臟模型的需求日益成長。這種多方面的細分分析將使相關人員能夠識別量身定做的機會並準確地解決市場空白。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 增加政府和機構對生命科學和毒理學研究的資助
      • 對個人化醫療和針對患者的治療方法的需求不斷增加
      • 肝病及相關健康併發症的盛行率
    • 限制因素
      • 先進肝臟模型的開發和製造成本高昂
    • 機會
      • 投資和資助生物醫學研究和創新肝臟模擬技術
      • 組織工程和3D生物列印解決方案的技術進步
    • 任務
      • 人體肝臟模型核准流程中的監管要求和合規障礙
  • 市場區隔分析
    • 模型類型：簡單快速的篩檢能力推動了 3D 人體肝臟模型的需求
    • 最終用戶：生物技術公司擴大使用人體肝臟模型
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 人體肝臟模型市場（依模型類型）

  • 2D模型
  • 3D模型
  • 體外模型
  • 混合模式
  • In Silico模型
  • 肝臟類器官

7. 人類肝臟模型市場細胞來源

  • 永生化肝細胞株
  • 原代人類肝細胞
  • 幹細胞衍生模型

8. 人體肝臟模型市場（依應用）

  • 藥物研發
  • 教育
    • 生理學研究
    • 毒理學研究

9. 人體肝臟模型市場（依最終用戶）

  • 生技公司
  • 合約研究組織
  • 製藥公司
  • 研究部門

10.美洲人體肝臟模型市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11.亞太地區人體肝臟模型市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12.歐洲、中東和非洲人體肝臟模型市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Ascendance Bio
  • BioIVT LLC
  • Cellink Global by BICO Group AB
  • CN Bio Innovations Ltd.
  • Corning Incorporated
  • Cyfuse Biomedical KK
  • EISCO Scientific LLC
  • Emulate Inc.
  • Hurel Corporation
  • InSphero AG
  • Kirkstall Ltd
  • MIMETAS BV
  • NeurOmics, Inc.
  • Organovo Holdings Inc.
  • Pandorum Technologies Private Limited
  • PhoenixBio Co., Ltd.
  • STEMCELL Technologies Inc.
Product Code: MRR-43127F7278DC

The Human Liver Model Market was valued at USD 1.55 billion in 2024 and is projected to grow to USD 1.68 billion in 2025, with a CAGR of 8.53%, reaching USD 2.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.55 billion
Estimated Year [2025] USD 1.68 billion
Forecast Year [2030] USD 2.54 billion
CAGR (%) 8.53%

The development and refinement of human liver models has accelerated dramatically over the past decade, marking a pivotal moment in biomedical research and drug development. In an era where precision medicine and innovative therapeutic strategies are at the forefront, an in-depth understanding of liver models has become essential. This report delves into the evolution of liver models, examining the integration of advanced methodologies and emerging technologies that are redefining the approach to liver physiology, disease modeling, and toxicity assessment. As research challenges escalate and regulatory demands intensify, the need for models that closely replicate human liver functions is more urgent than ever. Researchers, clinicians, and decision-makers alike are now presented with sophisticated alternatives-ranging from traditional two-dimensional cultures to dynamic three-dimensional systems, each offering unique benefits and addressing specific limitations of conventional methods. The current landscape is characterized by a significant shift towards more complex and physiologically relevant in vitro environments, a transition driven by both technological ingenuity and an increasing demand for actionable data in preclinical testing. In this context, this report provides a structured exploration of the transformative shifts, segmentation nuances, regional trends, and key players that are collectively steering the future of human liver model research.

Transformative Shifts Driving the Evolution of Liver Model Technologies

Recent years have witnessed transformative shifts that are reshaping the human liver model landscape. Technological convergence in experimental biology, computational simulations, and bioengineering has led to the creation of models that mimic the complex architecture and functionality of the human liver with unprecedented accuracy. Significant advancements in tissue engineering have enabled researchers to build three-dimensional constructs that encapsulate cell-matrix interactions better than traditional two-dimensional cultures. Additionally, the integration of ex vivo and hybrid models has bridged conventional gaps by combining the realism of native tissue with the controllability of engineered systems. The advent of in silico modeling has further accelerated data analysis and prediction, allowing for real-time adjustments and improvements in model fidelity.

A noteworthy element in these transformative shifts is the iterative process of validation and optimization that is now integral to model development. This ensures that emerging models not only serve as effective platforms for drug discovery and toxicology studies but also provide robust tools for physiological investigations. On the technological front, automation and high-throughput screening have contributed heavily to accelerating these advances. As research continues to drive improvements in replicating the human liver's complex behavior, the paradigm shift towards more biologically relevant methods is also fueling increased collaboration between academia, industry, and regulatory agencies. These converging forces underscore the vibrant, dynamic nature of the industry, where continuous innovation meets rigorous scientific inquiry.

Key Segmentation Insights Shaping Market Dynamics

A deep dive into segmentation reveals several underlying trends that are instrumental in defining market dynamics and future growth trajectories. When analyzing the market based on model types, an array of distinct technologies is employed, including two-dimensional models, three-dimensional models, ex vivo models, hybrid constructs, in silico models, and liver organoids. Each model brings its own set of advantages in terms of biological relevance and scalability, enabling researchers to target specific challenges in drug discovery and toxicology studies. Complementarily, a segmentation based on cell source further distinguishes the market; choices range from immortalized liver cell lines and primary human hepatocytes to stem cell-derived models, each offering varying levels of physiological accuracy and reproducibility.

In addition, application-centric segmentation highlights the dual role of these models. While drug discovery remains a major application area-supported by the ability to simulate metabolic pathways and signaling cascades-the educational sector has significantly benefited from advancements in physiology and toxicology studies. This dual focus facilitates a comprehensive understanding of liver functionality and underlines new educational practices enhanced by real-world data. Moreover, the segmentation based on end users further segments the market into biotechnology companies, contract research organizations, pharmaceutical companies, and research laboratories. The diversity in end-user profiles not only reflects a broad adoption of these models across various sectors but also illustrates the growing need for tailored liver models that match the specific requirements of each segment. This multifaceted segmentation analysis ensures that stakeholders can identify tailored opportunities and address market gaps with precision.

Based on Model Type, market is studied across 2D Models, 3D Models, Ex Vivo Models, Hybrid Models, In Silico Models, and Liver Organoids.

Based on Cell Source, market is studied across Immortalized Liver Cell Lines, Primary Human Hepatocytes, and Stem Cell-Derived Models.

Based on Application, market is studied across Drug Discovery and Education. The Education is further studied across Physiological Studies and Toxicology Studies.

Based on End Users, market is studied across Biotech Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Laboratories.

Regional Analysis: Global Perspectives on the Liver Model Sector

Regional dynamics play a critical role in shaping the development and adoption of human liver models. Market analysis indicates that different regions are prioritizing different aspects of technological advancement and regulatory frameworks. For instance, in the Americas, robust investment in biotechnology and healthcare infrastructure has paved the way for rapid adoption of innovative liver models in both industrial and academic settings. The mature ecosystem in this region supports a high level of collaboration among stakeholders, driving advancements through coordinated research and development efforts.

In contrast, the combined regions of Europe, the Middle East, and Africa are witnessing tailored investments designed to overcome regional healthcare challenges while balancing ethical and regulatory considerations. In these areas, traditional research methodologies are increasingly giving way to more sophisticated, hybrid approaches that integrate both ex vivo and in silico techniques. Meanwhile, the Asia-Pacific region stands out for its focused emphasis on scalability and cost-effectiveness. Rapid economic growth coupled with an expansive network of research institutions has catalyzed new product development and increased the overall global footprint of human liver models. Taken together, these regional insights underscore how localized market forces and strategic investments shape the adoption of liver models across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Spotlight: Leading Industry Players in Liver Modeling

The competitive landscape of liver model development is marked by the presence of several forward-thinking companies that are redefining the field. Industry leaders such as Ascendance Bio and BioIVT LLC have emerged as innovator hubs, consistently pushing the boundaries of technology. Significant contributions from companies like Cellink Global by BICO Group AB and CN Bio Innovations Ltd. have brought advanced tissue engineering capabilities into sharper focus, while established names such as Corning Incorporated demonstrate an enduring commitment to quality and reliability. Equally, Cyfuse Biomedical K.K. and EISCO Scientific LLC are gaining traction by offering novel approaches to bioprinting and model validation, thereby reinforcing the need for highly physiologically relevant systems.

Other key players, including Emulate Inc., Hurel Corporation, and InSphero AG, have systematically integrated emerging technologies to enhance model precision and usability. Companies like Kirkstall Ltd, MIMETAS B.V., and NeurOmics, Inc. are notable for their contributions toward merging traditional cell culture techniques with state-of-the-art engineering innovations. Organovo Holdings Inc. and Pandorum Technologies Private Limited have also been instrumental in redefining biological fabrication for comprehensive tissue modeling. Additionally, PhoenixBio Co., Ltd. and STEMCELL Technologies Inc. ensure that continuous product enhancements keep pace with evolving research demands. The cumulative impact of these organizations reflects a market driven by relentless innovation and vigorous competition, fostering an environment where quality, reliability, and scalability are equally prioritized.

The report delves into recent significant developments in the Human Liver Model Market, highlighting leading vendors and their innovative profiles. These include Ascendance Bio, BioIVT LLC, Cellink Global by BICO Group AB, CN Bio Innovations Ltd., Corning Incorporated, Cyfuse Biomedical K.K., EISCO Scientific LLC, Emulate Inc., Hurel Corporation, InSphero AG, Kirkstall Ltd, MIMETAS B.V., NeurOmics, Inc., Organovo Holdings Inc., Pandorum Technologies Private Limited, PhoenixBio Co., Ltd., and STEMCELL Technologies Inc.. Recommendations for Industry Leaders to Capitalize on Emerging Trends

Industry leaders are encouraged to adopt a multi-pronged strategy to harness the burgeoning opportunities in the human liver model sector. First, it is essential to invest in interdisciplinary collaborations that fuse expertise in tissue engineering, computational biology, and regenerative medicine. Such collaborations not only spur breakthrough innovations but also facilitate broader adoption of models that accurately mirror human physiology. Embracing state-of-the-art automation and high-throughput screening technologies will further enhance model reproducibility and accelerate preclinical studies, making your operations more competitive in the ever-evolving market landscape.

Second, consider targeting innovative product portfolio expansion strategies. Leveraging insights from advanced segmentation analyses-including model types, cell sources, application fields, and end-user profiles-can pinpoint specific market opportunities. Industry players who customize their offerings to meet sector-specific needs-whether for drug discovery or educational applications-will likely gain a strategic advantage. Additionally, scaling by addressing regional nuances is recommended; tailored regional partnerships or localized research initiatives can help capitalize on the distinct market dynamics present in the Americas, Europe, the Middle East and Africa, as well as the Asia-Pacific.

Finally, adopting rigorous validation protocols and pursuing regulatory alignment is paramount. Clear standards in model performance and reproducibility not only build trust with stakeholders but also pave the way for smoother market entry and integration into regulatory frameworks. By proactively engaging with these strategic imperatives, industry leaders will be well-positioned to drive innovation, secure market leadership, and better address emerging global health challenges.

Conclusion and Future Outlook for Human Liver Model Research

In conclusion, the advances in human liver modeling are reshaping the landscape of biomedical research and drug development. The integration of innovative techniques, from two-dimensional cultures to complex three-dimensional organoids and in silico platforms, is enabling breakthroughs that were once considered unattainable. As the market becomes increasingly segmented-by model types, cell sources, applications, and end-user demographics-the industry is poised for significant growth and diversification.

The analysis illustrates that transformative shifts are fueled by relentless innovation, cross-disciplinary collaborations, and regional strategic investments. Technological advancements in automation, high-throughput screening, and tissue engineering have raised the bar, ensuring that the models not only replicate key liver functions but also offer enhanced utility in toxicity and physiological studies. The competitive landscape, which features a blend of established giants and nimble startups, continues to drive the evolution of liver models, creating a robust foundation that supports next-generation drug discovery and clinical research.

Looking ahead, continued investments in research, a focus on scalable solutions, and adherence to robust regulatory standards will be critical. By recognizing and leveraging emerging trends, industry stakeholders will be able to navigate an increasingly complex market with precision and confidence, establishing pathways for sustained innovation and growth in the years to come.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising government and institutional funding for life sciences and toxicological studies
      • 5.1.1.2. Increase in demand for personalized medicine and patient-specific therapies
      • 5.1.1.3. Escalating prevalence of liver diseases and associated health complications
    • 5.1.2. Restraints
      • 5.1.2.1. High development and manufacturing costs of advanced liver models
    • 5.1.3. Opportunities
      • 5.1.3.1. Investments & funding in biomedical research and innovative liver simulation technologies
      • 5.1.3.2. Technological advances in tissue engineering and 3D bioprinting solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory requirements and compliance obstacles in the human liver model approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Model Type: Rising demand for 3D human liver model for their simplicity and rapid screening capabilities
    • 5.2.2. End Users: Growing usage of human liver model in biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Liver Model Market, by Model Type

  • 6.1. Introduction
  • 6.2. 2D Models
  • 6.3. 3D Models
  • 6.4. Ex Vivo Models
  • 6.5. Hybrid Models
  • 6.6. In Silico Models
  • 6.7. Liver Organoids

7. Human Liver Model Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Immortalized Liver Cell Lines
  • 7.3. Primary Human Hepatocytes
  • 7.4. Stem Cell-Derived Models

8. Human Liver Model Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Discovery
  • 8.3. Education
    • 8.3.1. Physiological Studies
    • 8.3.2. Toxicology Studies

9. Human Liver Model Market, by End Users

  • 9.1. Introduction
  • 9.2. Biotech Companies
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies
  • 9.5. Research Laboratories

10. Americas Human Liver Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Liver Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Liver Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Ochre Bio and GSK join forces to accelerate hepatology drug discovery
    • 13.3.2. Boehringer Ingelheim and Ochre Bio partner to accelerate regenerative liver therapy discovery
    • 13.3.3. PhoenixBio's innovative humanized liver chimeric mouse models transform preclinical drug testing
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Ascendance Bio
  • 2. BioIVT LLC
  • 3. Cellink Global by BICO Group AB
  • 4. CN Bio Innovations Ltd.
  • 5. Corning Incorporated
  • 6. Cyfuse Biomedical K.K.
  • 7. EISCO Scientific LLC
  • 8. Emulate Inc.
  • 9. Hurel Corporation
  • 10. InSphero AG
  • 11. Kirkstall Ltd
  • 12. MIMETAS B.V.
  • 13. NeurOmics, Inc.
  • 14. Organovo Holdings Inc.
  • 15. Pandorum Technologies Private Limited
  • 16. PhoenixBio Co., Ltd.
  • 17. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN LIVER MODEL MARKET MULTI-CURRENCY
  • FIGURE 2. HUMAN LIVER MODEL MARKET MULTI-LANGUAGE
  • FIGURE 3. HUMAN LIVER MODEL MARKET RESEARCH PROCESS
  • FIGURE 4. HUMAN LIVER MODEL MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN LIVER MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN LIVER MODEL MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY HYBRID MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 238. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 239. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024